52nd week of 2008 patent applcation highlights part 41 |
Patent application number | Title | Published |
20080317789 | Carrageenan Process - The present invention discloses a process for treating precipitated carrageenan, comprising the steps of (a) treating the precipitated carrageenan with an aqueous treatment solution containing an alkali or a salt, (b) washing the treated precipitated carrageenan in water, and (c) drying the washed precipitated carrageenan. | 2008-12-25 |
20080317790 | Process for Treatment of Kappa Carrageenan - The present invention relates to a process for treating precipitated carrageenan, comprising the steps of (a) treating the precipitated carrageenan with an aqueous treatment solution containing an alkali or a salt, (b) washing the treated precipitated carrageenan in water, and (c) drying the washed precipitated carrageenan. | 2008-12-25 |
20080317791 | Kappa Carrageenan - Disclosed is a carrageenan composition comprising sodium, potassium, calcium and magnesium. | 2008-12-25 |
20080317792 | Composition Based on Mineral Concentrates Derived From Precious Stones - The invention relates to a composition based on mineral concentrates. | 2008-12-25 |
20080317793 | Method for Make-Up or Care of the Nails - The present invention relates to a method for make-up and/or care of the nails comprising gluing onto the nail, by means of an adhesive, a flexible sheet comprising at least one layer of at least one organic and/or inorganic material, the organic or inorganic material and/or the adhesive containing at least one silicone compound, said sheet having a thickness in the range from 1 μm to 2 mm. The invention also relates to a kit for make-up or care of the nails, as well as an article for make-up or care of the nails. | 2008-12-25 |
20080317794 | Agglomerate Particles, Method for Producing Nanocomposites, and the Use Thereof - The invention relates to agglomerate particles which are constructed from agglomerated nanoscale primary particles and also to a method for incorporation of these particles in a polymer matrix and to the use of these agglomerate particles. | 2008-12-25 |
20080317795 | HIGHLY CHARGED MICROCAPSULES - The invention encompasses compositions containing sol-gel microcapsules that are highly positively charged. The sol-gel capsules generally contain additives. The invention also encompasses methods for producing highly charged microcapsules using cationic additives which can include cationic polymers. The methods allow for the encapsulation of polar or non-polar active ingredients. | 2008-12-25 |
20080317796 | HAIR CARE COSMETIC COMPOSITION - This hair care cosmetic composition contains (A) colloidal silica core/silicone shell particles consisting of (1) 90 wt % to 10 wt % cores of colloidal silica and (2) 10 wt % to 90 wt % shells of polyorganosiloxane represented by the mean formula R | 2008-12-25 |
20080317797 | TOOTH WHITENING PRODUCTS AND METHODS OF MAKING THE SAME - A dissolving strip for tooth whitening the strip having at least a first tooth contacting layer and a second outer layer. The first tooth contacting layer has a solid tooth whitening active in an amount which reacts within a predetermined time when placed on a tooth. The second outer layer has a blend of polymers having different molecular weights; the blend of polymers being selected to dissolve after the predetermined time has elapsed. The outer layer contains the tooth whitening active on said tooth until the active is substantially used up. A method of forming a dissolving tooth whitening strip is also provided, in which the outer layer is formed on a backing layer followed by the inner layer being formed on the outer layer. | 2008-12-25 |
20080317798 | Disposable Nonwoven Cleansing Mitt - A disposable nonwoven cleansing mitt adapted to be retained on a user's hand during use is provided. The disposable nonwoven cleansing mitt is releasably carrying a personal care composition. | 2008-12-25 |
20080317799 | NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME - The present invention relates to methods and compositions for treating pulmonary infection. In particular, the present invention provides nanoemulsion compositions and methods of using the same to treat bacteria associated with biofilms (e.g., found in pulmonary infections). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine), industrial, and research applications. | 2008-12-25 |
20080317800 | Biocidal Composition - The present invention relates to a biocidal composition, a method for its production and the use of the biocidal composition. | 2008-12-25 |
20080317801 | Control of Rodents - Control of Rodents A particulate mixture for use in the control of rodents which comprises a mixture of a plurality of bait particles and a plurality of non-bait particles, wherein each bait particle comprises matter edible by a rodent and a rodenticide and wherein each non-bait particle comprises matter edible by a rodent and has a flavour different from the flavour of a bait particle and wherein the non-bait particles are distinguished from the bait particles by at least one physical characteristic selected from size, shape, surface texture and internal texture. A non-bait particulate food for rodents as use in the control of rodents, when presented in admixture with bait particles to rodents, to encourage consumption of the bait particles. Such non-bait particulate food comprises dry extruded pellets of cereal meal and dried powdered crustacean. | 2008-12-25 |
20080317802 | Air Filter Having Antimicrobial Property - The present invention relates to an antimicrobial composition having antibacterial and antifungal properties and to an air filter manufactured using the composition. The filter of the present invention, comprising a filtration media treated with the antimicrobial composition having antibacterial and antifungal properties, has excellent antibacterial and antifungal properties, and thus can prevent the bacteria and fungi filtered by the filter from propagating in the filter. | 2008-12-25 |
20080317803 | Aqueous Rodenticide Formulations - The present invention comprises novel aqueous rodenticide formulations, cereal grains treated with these formulations, and methods of controlling rodents based on these formulations. | 2008-12-25 |
20080317804 | NEEM OIL LOTION PREPARATION AND WIPE - Provided in embodiments of the present invention is a neem oil lotion preparation impregnated in a fabric wipe to enable individualized application of an organic pesticide on human skin or a plant. In one embodiment, a wipe includes a fabric sheet impregnated with neem oil, an emulsifier, an emollient, a preservative, and water. In additional embodiments, the neem oil wipe may further be impregnated with a humectant and a fragrance. | 2008-12-25 |
20080317805 | LOCALLY ADMINISTRATED LOW DOSES OF CORTICOSTEROIDS - This invention provides for using a locally delivered low dose of a corticosteroid to treat pain caused by any inflammatory disease including sciatica, herniated disc, stenosis, mylopathy, low back pain, facet pain, osteoarthritis, rheumatoid arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug depot. | 2008-12-25 |
20080317806 | Antiparasitic Compounds - A compound of Formula (A), wherein R | 2008-12-25 |
20080317807 | STRONTIUM FORTIFIED CALCIUM NANO-AND MICROPARTICLE COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF - Compositions containing strontium fortified calcium nanoparticles and/or microparticles, and methods of making and using thereof are described herein. The strontium fortified calcium compounds contain calcium ions, calcium atoms, strontium ions, strontium atoms, and combinations thereof and one or more anions. Exemplary anions include, but are not limited to, citrate, phosphate, carbonate, and combinations thereof. The particles can be formulated for enteral or parenteral administration by incorporating the particles into a pharmaceutically carrier. The compositions can further contain one or more active agents useful for bone diseases or disorders, such as vitamin D, growth factors, and combinations thereof. The compositions can be used to treat or prevent one or more bone diseases or disorders of the bone, such as osteoporosis. Alternatively, the particles can be coated onto a substrate, such as the surface of an implant. The coatings can be used to improved biocompatibility of the implant, prevent loosening of the implant, reducing leaching of metal ions from metallic implants, and reduce corrosion. The coatings can be applied to the substrate using a variety of techniques well known in the art. In one embodiment, the coating is applied using electrophoretic deposition. The use of nano- and/or microparticles that provide high surface area helps to improve interfacial strength between the coating and the implant, which allows for the use of lower sintering temperatures. Lowering sintering temperatures minimizes or prevents thermal decomposition of the coating material and/or degradation of the implant material. | 2008-12-25 |
20080317808 | Hyarulonic Acid Derivative Based Three Dimensional Matrix - Use of a biological material containing: e) a three-dimensional matrix based on a hyaluronic acid derivative and optionally f) chondrocytes and/or mesenchymal cells partially or completely differentiated towards chondrocytes for the preparation of a graft to be surgically implanted into a joint cartilage damaged by or to be protected against a degenerative and/or inflammatory pathology. | 2008-12-25 |
20080317809 | Use of K -252a and Kinase Inhibitors for the Prevention or Treatment of Hmgb1-Associated Pathologies - The present invention relates to the use of K-252a, a physiologically active substance produced by microorganisms, and of its salts or synthetic and/or chemically modified derivatives for the prevention or treatment of HMGB1 associated pathologies. More particularly, the present invention relates to the use of K-252a for the prevention or treatment of restenosis. | 2008-12-25 |
20080317810 | Methods and Compositions for Reducing Oxalate Concentrations - The present invention provides methods and compositions for oxalate degradation. The present invention comprises devices comprising oxalate-reducing enzymes. The enzymes may be directly attached or incorporated in coatings on the devices. Such devices are useful in treatments where oxalate or oxalic acid deposits interfere. Methods for making and using such medical devices are also included. | 2008-12-25 |
20080317811 | Treatment of Cancer Using Tlr3 Agonists - The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by assessing the expression of TLR3 receptor by cancer cells. | 2008-12-25 |
20080317812 | SPACER WITH A COATING THEREON FOR USE WITH AN IMPLANT DEVICE - The present invention relates to a spacer, such as a polymeric spacer, for use with an implant device, e.g., a bone plate, for splinting a fracture of a bone. The spacer includes a body defining a bone healing surface, wherein at least a portion of the bone healing surface has a coating which includes a therapeutic agent, a polymeric carrier, and a buffer medium to stimulate bone growth and/or promote fracture healing. A kit is also disclosed which includes one or more of the spacers, at least one bone plate, and optionally one or more bone screws for securing he bone plate to bone. A method for promoting fracture healing in bone is further disclosed which includes securely situating a coated portion of the spacer adjacent bone. | 2008-12-25 |
20080317813 | Nanobead releasing medical devices - Medical devices comprising nanobeads encapsulating one or more bioactive agents and methods of use thereof are provided. | 2008-12-25 |
20080317814 | Tube for Connecting Marteriovenous and Interposition for Medical Operation - Disclosed herein are a tube for arteriovenous anastomosis useful in hemodialysis patients and an insert for use in medicinal operation in the body. The tube or the insert are repetitively treated with a medicament on the surface thereof, which provides stable communication between an artery and a vein of a patient under hemodialysis and can greatly reduce stenosis at arteriovenous connections by releasing the medicament at a suitable rate over a prolonged period of time. | 2008-12-25 |
20080317815 | Induction of a physiological dispersion response in bacterial cells in a biofilm - One aspect of the present invention is directed to a composition. The composition includes a dispersion inducer comprising: | 2008-12-25 |
20080317816 | POROUS OBJECTS HAVING IMMOBILIZED ENCAPSULATED BIOMOLECULES - A porous object includes a porous material having internal pore surfaces and external pore surfaces. Releasing material encapsulated biomolecules are immobilized on at least one of the internal pore surfaces, at least one of the external pore surfaces, or combinations thereof. | 2008-12-25 |
20080317817 | METHODS OF MANUFACTURING A DELIVERY SYSTEM FOR PROMOTING BONE GROWTH - A method for manufacturing a delivery system that includes a bone growth promoting material encapsulated within a water-absorbing, water-gelatinizable covering used to promote bone growth in order to repair a bone defect and/or strengthen a weakened bone region. The delivery system may be shaped and sized in order to fit within a bleeding wound (e.g., one that is formed in the gingiva when a tooth is extracted). The covering may be formed of a gelatinizable-gauze (e.g., oxidized cellulose) that forms a gel-like material when moistened with water. The delivery system may be stored in a moisture resistant package prior to use. | 2008-12-25 |
20080317818 | Interpenetrating Networks, and Related Methods and Compositions - The present invention provides interpenetrating polymeric networks (IPNs), and related methods and compositions. The hydrogel material of this invention comprises an interpenetrating network of two or more polymer networks, wherein at least one of the polymer networks is based on a biopolymer. Also provided is a method of producing the hydrogel material comprising, combining a first polymeric network with a second polymeric network, wherein the first polymeric network or the second polymeric network is based on a biopolymer. The present application also discloses devices manufactured from the IPN hydrogel material and uses thereof. | 2008-12-25 |
20080317819 | Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas - A contact lens for delivery of a multiplicity of drugs includes a lens body with a first drug incorporated in a first zonal area of the lens body and a second drug incorporated in a second zonal area of the lens body. The first and second drugs are dissimilar and the first and second zonal areas are spaced apart from one another. | 2008-12-25 |
20080317820 | Delivery System - A control release device for the delivery of active components, the device including; a rigid housing containing at least one discrete aperture therein, and a driving substance containing the active component(s) placed within the housing, characterized in that the driving substance swells in the presence of fluid, driving the substance and active components out of the housing through the apertures. | 2008-12-25 |
20080317821 | Lipase Inhibitors - The present invention provides lipase inhibitors containing dimers of flavan-3-ols derived from teas as well as foods and beverages and medicines containing said inhibitors. More specifically, the present invention provides lipase inhibitors containing at least one of assamicains represented by the formula: | 2008-12-25 |
20080317822 | Methods for Delivery of Nanosome Encapsulated Agents - Vitamins, minerals, antioxidants, and growth factors are encapsulated in nanosomes and the nanosomes suspended in beverages. The nanosomes effectively cross the through the stomach and into the blood stream to be delivered to cells while protecting the contents encapsulated in the cell from degradation prior to delivery to the final target. | 2008-12-25 |
20080317823 | High Pressure Processing of Bioactive Compositions - The present invention relates to a method of pressure treating a bioactive composition comprising at least one bioactive component to prevent the growth of at least one unwanted microorganism while retaining a desired level activity of the at least one bioactive component. The bioactive component is selected from one or more proteins protein hydrolysates, one or more lipids or lipid hydrolysates, one or more carbohydrates, one or more probiotic factors, or mixtures thereof. The pressure treatment is at a predetermined pressure from about 350 to 1000 MPa. | 2008-12-25 |
20080317824 | Chocolate Coated Spherical Filled Capsules - Described is a spherical coated capsule comprising a coating-free capsule having (i) a liquid or viscous core ( | 2008-12-25 |
20080317825 | Pharmaceutical Preparation that can be Administered Orally for Treating Fish, Production Method for Said Preparation and Use of the Latter - The present invention is directed to a pharmaceutical preparation for oral application for treatment of fish, in particular for vaccination of fish of the salmon family and other fish having a comparable digestive system against bacterial and/or viral infections, in particular against VHS and IHN. The invention is also directed to a method for producing the preparation. | 2008-12-25 |
20080317826 | POROUS KERATIN CONSTRUCTS, WOUND HEALING ASSEMBLIES AND METHODS USING THE SAME - A porous keratin construct for use in wound healing is disclosed. The porous keratin construct may be used standing alone or in combination with a synthetic foam backing layer. Either the porous keratin construct or the porous keratin construct and synthetic foam combination may be used in a wound therapy such as negative pressure wound therapy. An assembly for use in negative pressure wound therapy may comprise a porous keratin construct or porous keratin construct and synthetic foam combination, a wound drape to encapsulate the wound and the porous keratin construct or porous keratin construct and synthetic foam combination, and a vacuum source in fluid communication with the wound drape to apply a negative pressure to the area encapsulated by the wound drape | 2008-12-25 |
20080317827 | Methods and Devices for Delivering Therapeutic Agents to Target Vessels - Methods of preparing devices for delivering at least one therapeutic agent to a target vessel in a mammal, the devices prepared by such methods, and uses of such devices for delivering a therapeutic agent, such as an antiproliferative agent, to a target vessel. | 2008-12-25 |
20080317828 | Fentanyl compound-containing edible patch to be applied to oral mucosa - There is provided a film-type edible oral mucosal patch comprising a main ingredient, a fentanyl compound, contained in a base comprising (A) a semi-synthetic water-insoluble polymer compound, (B) a semi-synthetic water-soluble polymer compound, (C) a synthetic water-soluble polymer compound, (D) a water-soluble polyhydric alcohol and (E) a pH-adjusting agent. The oral mucosal patch consists of substances accepted as the food additives or pharmaceutical additives approved for oral administration, and is industrially efficiently produced and easily and safely used. | 2008-12-25 |
20080317829 | Method for the Production of a Wound Pad - The invention relates to a method for producing a wound pad, by means of which the permeability of the wound pad can be adjusted. The inventive method makes it possible to produce wound pads for a wide range of therapeutic applications. | 2008-12-25 |
20080317830 | Compositions and Methods for the Treatment of Wounds and Scar Tissue - Compositions for the treatment of wounds and/or scars are described herein. The compositions contain between 1 and up to 30% by weight, more preferably between 1 and 20%, most preferably between about 5 and 10% by weight particles, such as titanium dioxide or a similar material in a pharmaceutically acceptable base or carrier, such as petrolatum. The compositions are less greasy than petrolatum alone, and thus are more aesthetically pleasing. The compositions exhibit occlusive properties comparable to petrolatum. The compositions are absorbed into the skin, unlike petrolatum, and exhibit significant wound healing characteristics not observed with petrolatum alone. In one embodiment, the pharmaceutically acceptable base is petrolatum and the particles are titanium dioxide. The compositions can be used to treat complex, hard to heal wounds, such as diabetic ulcers; pressure sores, such as bed sores; lacerations; bite wounds; burns; penetrating wounds; surgical wounds, etc. The composition can also be used to promote normal healing of scar tissue. The compositions can also be used for the topical delivery of one or more active agent. The compositions can be used to reduce fine lines and wrinkles, and to rehydrate skin or to treat dry skin. | 2008-12-25 |
20080317831 | HEMOSTATIC SPONGE AND METHOD OF MAKING THE SAME - A device for promoting the clotting of blood includes a web of non-woven fibers of a polymer having a hemostatic agent disposed on the fibers. The fibers are randomly arranged to form the web. When the device is applied to a bleeding wound, at least a portion of the hemostatic agent comes into contact with blood to cause the blood to clot. A hemostatic sponge includes a melt-blown non-woven fibrous web of polymer material and a hemostatic agent that is attached to the fibers. A method of making a hemostatic sponge includes the steps of melting a polymer and combining the polymer with a hot air stream. A hemostatic agent is added to the melt. The melt with the hemostatic agent is then drawn into fibers and collected as a web. | 2008-12-25 |
20080317832 | TRANSDERMAL DELIVERY SYSTEM COMPRISING GLYCOPYRROLATE TO TREAT SIALORRHEA - In one aspect, the invention includes a method for treating sialorrhea, comprising the steps of identifying a patient afflicted with sialorrhea and administering a therapeutically effective amount of glycopyrrolate to the patient using a transdermal route of administration. In another aspect, the invention is a transdermal drug delivery system for treating a patient exhibiting sialorrhea, including a transdermal patch, a therapeutically effective amount of glycopyrrolate contained in the transdermal patch to alleviate sialorrhea, and a pharmaceutically acceptable carrier. The transdermal patch can be a single layer drug-in-adhesive patch, a multi-layer drug-in-adhesive patch, a matrix patch, or a reservoir patch. | 2008-12-25 |
20080317833 | Novel Anti-Inflammatory Androstane Derivatives - There are provided according to the invention pharmaceutical compositions comprising a compound of formula (I) | 2008-12-25 |
20080317834 | Compounds and methods for modulating cerebral amyloid angiopathy - The invention provides methods of inhibiting cerebral amyloid angiopathy. The invention further provides methods of treating a disease state characterized by cerebral amyloid angiopathy in a subject. | 2008-12-25 |
20080317835 | Personalized Nutrient Deficiency Assay Methods - Assays are preformed to determine nutrient deficiency levels in an individual to address the deficiencies and improve health and longevity. Nutraceutical and cosmeceutical products containing nanoencapsulated active ingredients are provided, in addition to dietary, exercise, sleep, and other lifestyle recommendations. | 2008-12-25 |
20080317836 | Topical compositions for anti-aging skin treatment - This invention discloses anti-aging skin treatment compositions and methods that utilize plant-based copper and zinc antioxidant complexes. | 2008-12-25 |
20080317837 | PEPTIDE EPITOPES OF APOLIPOPROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 2008-12-25 |
20080317838 | Liposomal Vaccine Compositions Comprising a Polysaccharide Antigen and a Protein Adjuvant - A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against | 2008-12-25 |
20080317839 | AMINO ACID LIPIDS AND USES THEREOF - This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects. | 2008-12-25 |
20080317840 | COMPOSITIONS AND METHODS FOR POLYMER-CAGED LIPOSOMES - The present invention provides liposomal compositions and methods of using such compositions in vitro and in vivo. In particular, the present invention provides stable, polymer-caged liposomes comprising a pH responsive delivery mechanism for delivery of nucleic acids, peptides, small molecules, drugs, etc. in vitro and in vivo. | 2008-12-25 |
20080317841 | Pharmaceutical Composition Containing Coated, Floating Particles - A dosage form exhibiting delayed transit time through the GI tract. The dosage form comprises a plurality of buoyant particles, each comprising an inner drug-containing core, an intermediate layer surrounding said core and a release rate-controlling outer coating. | 2008-12-25 |
20080317842 | Fast Wet-Massing Method for the Preparation of Calcium-Containing Compositions - The present invention relates to a novel process for the preparation of a granulate comprising a calcium-containing compound as an active substance. The method comprises a method for the preparation of a granulate comprising a calcium-containing compound as an active substance, the method comprising, i) feeding a granulation chamber with a composition comprising the calcium-containing compound, ii) wet-massing the composition with a granulation liquid optionally comprising a pharmaceutically acceptable binder for a time period of at the most 30 sec to obtain a wet granulate, iii) drying the thus obtained wet granulate. A granulate obtained by the present method is especially suitable in the preparation of solid dosage forms, in particular in the preparation of tablets. | 2008-12-25 |
20080317843 | NANOPARTICULATE FORMULATIONS OF MODAFINIL - The present invention is directed to compositions comprising a nanoparticulate modafinil compositions, or a salt(s), or an enantiomer(s), or a prodrug(s), or a polymorph(s) or derivative thereof, having improved bioavailability. The nanoparticulate modafinil composition formulation particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of dyssomnias, including but not limited to, narcolepsy, chronic fatigue, eating disorders, compulsive behaviors, ADHD, addictions, substance abuse, sleepiness, nervous system diseases, conditions, syndromes, and symptoms and related diseases, conditions, and symptoms. | 2008-12-25 |
20080317844 | Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Compositions Comprising Same - A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided. | 2008-12-25 |
20080317845 | Duloxetine Formulation - A duloxetine pellet formulation comprises: (i) a core including a desired amount of duloxetine; (ii) an enteric coating comprising hydroxypropylmethylcellulose phthalate (HPMCP) as an enteric polymer; and, optionally, (iii) a separating layer located between the core and the enteric coating, the separating layer including polyvinyl alcohol and a low molecular weight hydroxypropylmethylcellulose (HPMC). | 2008-12-25 |
20080317846 | Pulsatile release histamine H2 antagonist dosage form - A unit dosage form, such as a capsule or the like, for delivering drugs into the body in a circadian release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need at different times during the dosing period, i.e., mimicking the circadian rhythm and severity/manifestation of gastric acid secretion (and/or midnight gerd), predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations. | 2008-12-25 |
20080317847 | HYDROSTATIC DELIVERY SYSTEM FOR CONTROLLED DELIVERY OF AGENT - The present invention provides a hydrostatic delivery system including a hydrostatic couple and an agent of interest. The hydrostatic couple includes at least one hydrodynamic fluid-imbibing polymer, and at least one hydrostatic pressure modulating agent. This delivery system has the ability to control the release of one or more agents of interest within a fluid environment following zero-order kinetics. | 2008-12-25 |
20080317848 | Oral Dosage Forms for Propiverine or Pharmaceutically Acceptable Salts Thereof Having Prolonged Release of the Active Agent - By suitable retardation oral pharmaceutical compositions containing propiverine or one or several pharmaceutically acceptable salts thereof in an amount of 4 mg to 60 mg propiverine and having a prolonged release of the active agent are produced. Preferably a blend of active agent and optionally one or more acidic substances having a pK | 2008-12-25 |
20080317849 | Method for Improving the Medical Treatment of Pain - Methods for improving pain management in a mammal, the methods comprising administering a combination of a strontium-containing compound and a second therapeutically and/or prophylactically active substance selected from the group consisting of analgesic agents, anti-inflammatory agents and palliative agents to the mammal. Pharmaceutical compositions for use in such methods, comprising a strontium-containing compound and a second therapeutically and/or prophylactically active substance selected from the group consisting of analgesic agents, anti-inflammatory agents and palliative agents. | 2008-12-25 |
20080317850 | Buccal Delivery System - A buccal delivery system capable of being blended in a normal dry powder process and compressed using a standard tabletting machine, said buccal delivery system comprising a matrix of: (a) an effective amount of one or more active ingredients; (b) an amount of one or more polyethylene glycols or derivatives thereof having a molecular weight between 1000 to 8000 sufficient to provide the required hardness and time for dissolution of the matrix; (c) 0.05-2% by weight of the total matrix of one or more suspending agents; (d) 0.05-2% by weight of the total matrix of one or more flowing agents; and (e) 0.05-2% by weight of the total matrix of one or more sweeteners. | 2008-12-25 |
20080317851 | IMMEDIATE RELEASE DOSAGE FORMS CONTAINING SOLID DRUG DISBURSIONS - High loading immediate release dosage forms containing at least 30 wt % of a solid drug dispersion, at least 5 wt % of a disintegrant and a porosigen are disclosed that exhibit excellent strength and aqueous solubility. | 2008-12-25 |
20080317852 | Pharmaceutical Combination - A pharmaceutical formulation for the treatment of HIV is provided. The formulation is a combination of a nucleoside reverse transcriptase inhibitor and a nucleotide reverse transcriptase inhibitor in which the combination has an increased stability over prior art combination therapies. The invention also provides a pharmaceutical product containing the formulation. | 2008-12-25 |
20080317853 | Mouth Dissolving Pharmaceutical Composition and Process for Preparing the Same - Disclosed herein is a orally disintegrating and/or dissolving oral pharmaceutical composition, comprising one or more active pharmaceutical ingredients, one or more fillers having particle size of 100 microns or above, a high and desirable amount of silicon dioxide, one or more disintegrating agents, optionally effervescent couple, wherein said composition has good organoleptic properties like desired mouth feel and fast oral disintegration time. | 2008-12-25 |
20080317854 | PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED SOLID DOSAGE FORM - The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of =500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and force. | 2008-12-25 |
20080317855 | Particulate Compositions Comprising Alginate and/or Alginic Acid - An ingestible particulate composition comprises: a. an alginate and/or alginic acid; b. a bicarbonate and/or carbonate; c. an organic acid; and d. an agglomerant, being a compound, such as a low molecular weight polyol, which allows the particulate composition to flow yet which substantially does not release fine particulates into the air. Resulting particulate compositions have excellent flow characteristics, dust suppression, organoleptic properties and stability. They are highly suitable for administration direction into a patient's mouth, and ingested to alleviate oesophageal and gastric conditions. | 2008-12-25 |
20080317856 | Compositions Containing A Capillary -Active System With Application -Relevant Differentiability, And The Use Thereof - This invention relates to compositions with a capillary-active system with application-relevant differentiability and synergistic potential for use in mammals, especially humans. | 2008-12-25 |
20080317857 | V-Atpase Inhibitors of Use in the Treatment of Septic Shock - The use of vacuolar ATPase inhibitors in the prevention and/or treatment of septic shock is herein described. Vacuolar ATPase inhibitors are selected among products of natural, semi-synthetic or synthetic origin. | 2008-12-25 |
20080317858 | FORMULATIONS OF N-(2-ACETYL-4,6-DIMETHYLPHENYL)-3--2-THIOPHENECARBOXAMIDE - Provided herein are intravenous and oral formulations of N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide. Also provided are methods of making and using the formulations. | 2008-12-25 |
20080317859 | Stabilization of Testosterone Within Transdermal Devices - The present invention relates to the chemical stabilization of testosterone contained in self-adhesive transdermal devices by way of the association of a desiccant agent with said device within a sealing packaging. The use of a desiccant agent makes it possible to limit the chemical degradation of the testosterone to androstenedione and other impurities and accordingly ensures storage of said device over periods of up to thirty-six months. | 2008-12-25 |
20080317860 | Use of a Polysaccharide Which is Excreted by the Vibrio Diabolicus Species For the Engineering of Non-Mineralized Connective Tissue - The invention relates to the use of a polysaccharide which is excreted by the | 2008-12-25 |
20080317861 | Polymeric Materials and Methods - Chimeric polymer compositions and methods are provided in which a plurality of carbohydrate moieties and amino acids form the backbone of a polymer. Most preferably, the polymer includes alternating saccharide and peptide portions to form the chimeric polymer. | 2008-12-25 |
20080317862 | Organic Compounds Comprising a Glycopyrrolium Salt - Medicaments comprising (A) an antimuscarinic agent and (B) a corticosteroid for the treatment of inflammatory or obstructive airways diseases. | 2008-12-25 |
20080317863 | Pharmaceutical Compositions Useful in the Transmucosal Administration of Drugs - There is provided pharmaceutical compositions in the form of homogeneous interactive mixtures, which compositions comprise a pharmacologically-effective amount of an active ingredient in the form of microparticles of a size between about 0.5 μm and about 10 μm, which particles are attached to the surfaces of larger carrier particles with a size range of between about 10 and about 100 μm. The carrier particle material is preferably bio- and/or mucoadhesive in its nature. | 2008-12-25 |
20080317864 | Chitosan and Heparin Nanoparticles - The invention is aimed at nanoparticulate systems for the controlled release of heparin. It is specifically aimed at nanoparticulate systems comprising chitosan, heparin and optionally a polyoxyethylenated derivative, and which are ionically cross-linked, as well as being aimed at processes for obtaining them. | 2008-12-25 |
20080317865 | Quench liquids and washing systems for production of microparticles - The present invention provides coacervation methods forming compositions for the sustained release water soluble active agents, including biologically active polypeptides. The invention further relates to the discovery of improved non-aqueous quench liquids and washing systems, which enable a reduction in the amount and concentration of hardening agents such as heptane used to produce microparticles, while providing acceptable product yields and residual solvent levels. | 2008-12-25 |
20080317866 | COLLAGEN-BASED MICROSPHERES AND METHODS OF PREPARATION AND USES THEREOF - A method of manufacture of ECM microparticles incorporating bioactive molecules for drug delivery has been developed, using a modified emulsification method or a water-in-oil-phase-separation method. The microspheres are photochemically crosslinked to control the release of the bioactive molecules for better drug delivery usage without compromising the biocompatibility of the crosslinked structures. The method uses mild fabrication conditions and simple processes, no toxic chemical crosslinking reagent, which may cause cytotoxicity and calcification after implantation, no organic solvents, which may reduce drug availability and bioactivity, and no vigorous stirring action, which may fragmentize material with poor shape and mechanical stability and thus destabilize the emulsion. The resulting microparticles or microspheres are of controlled size, controlled release, highly biocompatible, and useful for drug delivery as well as cell culture. | 2008-12-25 |
20080317867 | Cosmetic System, and Method for Disguising Skin Defects - The present invention provides a cosmetic system for disguising dermatological blemishes. The cosmetic system includes a viscous silicone material and a catalyst. The silicone material is pigmented with a cosmetic pigment according to a selected skin tone. In one aspect, the cosmetic system also includes a flocking agent. The flocking agent is mixed within the silicone material or the catalyst to provide texture. The cosmetic system also includes at least two cartridges. The cartridges hold the viscous silicone material and the catalyst, separately. Optionally, the cosmetic system includes a dispensing gun. The dispensing gun has a tip through which the silicone material and the catalyst may be dispensed, whereupon the silicone material and the catalyst are mixed and applied to a user's skin for curing. A method for disguising dermatological blemishes is also provided herein. | 2008-12-25 |
20080317868 | COMPOSITION FOR IMPROVING MEMBRANE COMPOSITION AND FUNCTIONING CELLS - It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises:
| 2008-12-25 |
20080317869 | Method and compositions for treatment of ADD/ADHD, depression, memory problems and other conditions - Disclosed herein are compositions and methods for treating a variety of mood and behavioral disorders, including attention deficit hyperactivity disorder (ADHD), anxiety, depression, memory loss, as well as other conditions. Also disclosed herein are methods for diagnosing certain conditions, such as ADHD, using these compositions. | 2008-12-25 |
20080317870 | Compositions and Mehtods for Treating and Preventing Cancer Using Analogs of Vitamin D - Disclosed are compositions and methods used to treat and/or prevent cancer and metabolic diseases, such as psoriasis. In one aspect, the present invention pertains to the use of cross-linking analogs of vitamin D and its metabolites employed for the treatment of prostate cancer. | 2008-12-25 |
20080317871 | Use of Hydrochloric Acid For the Manufacture of a Medicament For the Treatment of Hypertension - A method of treating hypertension by administering to a patient an aqueous solution of HCl having a pH from 3 to 6.9 for a period of from 0.5 to 6 years and a method of treating a calculus disease by administering an aqueous solution of HCl having a pH from 3 to 6.9 are disclosed. | 2008-12-25 |
20080317872 | Final Finish Aftershave - The irritation experienced by many males resulting from shaving with a razor and/or a depilatory has been well documented. There are several causes, the most outstanding being the tendency of the clipped hair to curl and grow inward beneath the skin surface. The shaved surface then bumps as the combined result of shaving irritation and clipped hairs which have not grown straight through the skin. | 2008-12-25 |
20080317873 | Pain Relief Compositions - A pain relieving composition for topical application is provided that includes magnesium sulfate (Epsom salts). The composition provides magnesium sulfate in an amount effective for providing pain relief. The composition has a viscosity effective for allowing topical application of the composition to an afflicted area where the magnesium sulfate is absorbed through the skin to provide pain relief. The composition provides the novel benefits of being portable, easily dispensed, and provides a higher concentration of applied magnesium sulfate than the traditional dispensing method of soaking solutions. | 2008-12-25 |
20080317874 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) - A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal. | 2008-12-25 |
20080317875 | Inhibitor of PI3 kinase-dependent inflammatory cytokine synthesis and method for inhibiting the same - The present invention provides a novel inhibitor for inhibiting synthesis of a PI3 kinase-dependent inflammatory cytokine in vivo in a vertebrate and a method for inhibiting the same. More particularly, the present invention provides a suppressor for suppressing a cell-mediated immune response and a method for suppressing the same, as well as an activator for activating a humoral immune response and a method for activating the same. In the present invention, by administering Li ion to a living body to inhibit synthesis of an inflammatory cytokine, a cell-mediated immune responses can be suppressed, and immune-mediated inflammatory disorders (IMIDs) can be treated. | 2008-12-25 |
20080317876 | USE OF A MAGNESIUM ISOTOPE FOR TREATING HYPOXIA AND A MEDICAMENT COMPRISING THE SAME - The present invention describes the use of the magnetic magnesium isotope | 2008-12-25 |
20080317877 | Biofilm Remover - A composition for the removal of biofilms from substrate surfaces formed by reacting: (a) one or more quaternary halide surfactants with (b) a source of reactive bromine ions in the ratio of 1 halide ion forming part of the quaternary surfactant to 0.05 to 8 moles of bromine ions in aqueous solution. | 2008-12-25 |
20080317878 | Herbal Therapy for the Treatment of Food Allergy - The present invention provides herbal formulas, and compositions thereof, that can treat or reduce the severity, intensity, or duration of food allergy and food allergyrelated symptoms. The compositions may optionally include one or more adjuvants, cytokines, encapsulating materials, or pharmaceutically acceptable carriers or excipients, and may be administered prior to, during, or after the development of food allergy-related symptoms in a patient in need thereof. | 2008-12-25 |
20080317879 | Herb Composition for Asthma Maintenance Therapy and Manufacturing Method Thereof - The present invention relates to a herb composition for asthma maintenance therapy based on Chungsangboha-tang, which is known to be effective in asthma, capable of reducing the long-term suffering of asthma patients and improving their quality of lives and a manufacturing method thereof. The herbal composition of the present invention is characterized by comprising 5-18 parts by weight of | 2008-12-25 |
20080317880 | PLANT ISOFLAVONE AND ISOFLAVANONE O-METHYLTRANSFERASE GENES - The invention provides enzymes that encode O-methyltransferases (OMTs) from | 2008-12-25 |
20080317881 | METHOD FOR SUSTAINABLE TRANSGENE TRANSCRIPTION - The present invention relates to constructs and methods for improving expression of transgenes in plants, animals and humans. | 2008-12-25 |
20080317882 | Composistion Comprising Fremented tea Extract as the Main Component and Having Effect of Elevation Adiponectin Level - A composition capable of elevating blood adiponectin level and enlarging LDL particle size and thus lowering the concentration of small dense LDL in blood to thereby prevent diabetes and a heart disease such as a coronary artery disease or ameliorate the symptoms of these diseases, which originates in a natural material, shows a high safety without any side effect even in continuous intake over a long period of time, and is usable as a health food or drink. A composition comprising as the active ingredient a fermented tea extract which has an effect of elevating adiponectin level and an effect of enlarging LDL particle size. | 2008-12-25 |
20080317883 | METHODS FOR TREATING DEPRESSION - The present invention is a method for the treatment of depression comprising administering to a subject in need thereof a therapeutically effective amount of one or more carbamate compounds of Formula 1 and/or Formula 2 as herein defined and shown below for the treatment of depression. | 2008-12-25 |
20080317884 | Enhancing Disease Resistance In An Animal - A method to enhance disease resistance in an animal comprising feeding the animal a diet enriched in antioxidants and providing behavioral enrichment. In one embodiment, the behavioral enrichment comprises exercising the animal regularly effective to cause behavioral enrichment, wherein the feeding and exercising combination is effective to increase neutrophil phagocytosis and B cell percentages. | 2008-12-25 |
20080317885 | Compositions and Methods for Treating and Preventing Inflammatory and/or Degenerative Processes in Humans and Other Animals - Disclosed are compositions useful for treating Alzheimer's disease, atherosclerosis, arteriosclerosis, osteoarthritis and other degenerative joint diseases, Huntington's chorea, Parkinson's disease, optic atrophy, retinitis pigmentosa, macular degeneration, muscular dystrophy, aging-associated degenerative processes, asthma, dermatitis, laminitis, pemphigoid, pemphigus, reactive airway disease (e.g., COPD, IAD), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), multiple sclerosis, rheumatoid arthritis, periodontal disease, systemic lupus erythematosus, sarcoidosis, psoriasis, type I diabetes, ischemia-reperfusion injury, chronic inflammatory diseases, geriatric wasting, cancer cachexia, cachexia associated with chronic inflammation, sick feeling syndrome, and other inflammatory and/or degenerative diseases, disorders, conditions, and processes in humans and other animals. In one embodiment, the compositions include at least 4 of the following: a MMP1 inhibitor, a MMP2 inhibitor, a MMP3 inhibitor, a MMP7 inhibitor, a MMP9 inhibitor, an ADAMTS-4 inhibitor, a MMP13 inhibitor, and a MMP14 inhibitor. In another embodiment, the compositions include a curcuminoid, a polymethoxylated flavone, a catechin, and a boswellic acid. | 2008-12-25 |
20080317886 | Compositions for Preventing and Reducing Delayed Onset Muscle Soreness - The present invention relates to the compositions that enhance post-exercise recovery processes to increase both strength and muscle mass, replace glycogen stores, and prevent inflammation, resulting in the prevention and/or reduction of delayed onset muscle soreness. Additionally, it provides a feeling of muscle relaxation as well as a feeling of mental tranquility immediately following exercise. The composition consists of any or all high-glycemic sugars and/or polysaccharides (e.g., sucrose, glucose, maltodextrin), all essential amino acids and beta-hydroxy-beta-methylbutyrate and can include other amino acids sources (e.g. whey protein), performance enhancing agents (e.g., caffeine, L-glutamate), anti-inflammatory agents (e.g., ginger, boswellia, curcumen), antioxidants (vitamin C, vitamin E, selenium, polyphenols,), insulin-mimicking agents (cinnamon, Banaba), analgesics (e.g. aspirin, ibuprofen, naproxen, acetaminophen), and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof. | 2008-12-25 |
20080317887 | Compositions and Methods for Treating and Preventing Migrainous Headaches and Associated Symptoms - Compositions and methods of treating migrainous headaches and their associated symptoms are provided. Methods of treating migrainous headaches and their associated symptoms include administering a lipid-based composition containing feverfew extract and ginger extract sublingually to a patient in need thereof. Treatments are effective using low total administered amounts of feverfew and ginger extracts. | 2008-12-25 |
20080317888 | PROCESS FOR OBTAINING LIGNANS - Process for obtaining lignan from plant material by extraction with an extraction solvent and separation of the liquid fraction from the plant material. The separated liquid fraction containing the lignan product is subjected to further processing to remove cyanogenic sugars and other impurities. The resulting lignan containing product may be formulated for the treatment of various conditions, such as cancer, diabetes, hypertension, lupus, and atherosclerosis. | 2008-12-25 |